AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$OMER

HANISH ARNOLD C sold $282K of OMER

HANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.

Original reporting
SEC EDGAR · HANISH ARNOLD C
Published Aug 28, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The filing provides fresh data on insider holdings, offering a modest trading signal.

02

Market read

New insider sale information with limited material impact.

03

What to watch

No other insider activity reported; the market may have already priced in typical director sales.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filing discloses insider transactions; director exits are noteworthy but often low‑impact.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

Director Hanish Arnold C sold 15,000 shares for $282,094, reducing his stake to zero.

Expected impact

Modest short‑term downside pressure, likely 1‑2% dip.

Evidence & confidence

The sale size is modest but represents a complete exit by a board member, which can be interpreted as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to U.S. markets where OMER trades.

Global

Low

Counterpoint

What could challenge this read

The sale could be unrelated personal liquidity need, not a confidence issue.

Key entities

  • Company
    OMEROS Corp

    Biotech company listed on NASDAQ under ticker OMER.

  • Individual
    Hanish Arnold C

    Director of OMEROS Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OMER insider trading history →

Related articles

AUG 20
$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

fool.com3 min
AUG 14
$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

yahoo.com5 min
AUG 13
$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

investing.com4 min
AUG 12
$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

SEC EDGAR 8-K7 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min